BGB-3619

BGB-3619 is a small molecule inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, specifically targeting BRD2, BRD3, BRD4, and BRDT. Developed by BeiGene, it functions as an epigenetic modulator by binding to bromodomains and preventing the interaction between BET proteins and acetylated histones, thereby disrupting the transcription of key oncogenes such as MYC. Preclinical research indicates that BGB-3619 possesses potent anti-proliferative activity against various hematological malignancies, including leukemia and lymphoma. Furthermore, it has shown potential in overcoming resistance to tyrosine kinase inhibitors (TKIs) in solid tumors, such as melanoma and lung cancer, by inducing G1 phase cell cycle arrest in TKI-resistant cell lines.